The JPMorgan Healthcare Conference remains the event that sets the tone for the biotech year. Held each January in San Francisco, it is where deals get announced, strategies get unveiled, and the industry collectively takes its own temperature. Planning for the 2027 edition should start well before the invitations go out, because the people who get value from that week are the ones who prepared months in advance. Here is what to expect and how to approach it.
What the week actually is
It helps to be clear-eyed. The formal conference, company presentations to investors, is only a fraction of what matters. The real event is the enormous surrounding ecosystem: thousands of meetings in hotel lobbies, coffee shops, and rented suites across the city, satellite conferences and receptions, and a density of decision-makers found nowhere else in the industry. Most of the value comes from the meetings you schedule yourself, not from the sessions. Attending without a full calendar of pre-booked meetings is the single most common and most expensive mistake, because in that case you have paid an enormous amount to stand in the cold.
What will likely dominate the agenda
Based on where the industry sits heading into 2027, several themes look likely to shape the conversation. Obesity and metabolic disease will almost certainly remain the biggest commercial story, with the oral drug era now underway and next-generation combinations advancing. The M&A wave will be central, as large pharma continues buying to fill the revenue gaps left by looming patent expiries. Capital markets will be scrutinized closely, since the selective reopening of the IPO window in 2026 raised the question of whether access will broaden. China licensing will remain a major and somewhat fraught theme, given the scale of assets flowing out of Chinese biotech and the policy tension around it. Manufacturing and supply-chain reshoring is now a strategic topic rather than an operational one. And drug pricing policy will be a live concern as Medicare negotiation expands.
Who should actually go
Be honest about whether it is worth it, because the cost is substantial. It makes sense if you are raising money and can use the density of investors, if you are doing business development and can book meaningful partner meetings, if you are a public company engaging investors, or if you are a service provider whose customers will be there in force. It makes much less sense if you have no specific meetings to hold, no news to share, and no concrete objective, in which case the money is better spent elsewhere and you can follow the news from your desk.
How to prepare
The preparation is the whole game. Start booking meetings months ahead, since the calendars of the people you want to see fill up remarkably early, and by December the best slots are gone. Have a clear objective for each meeting rather than treating them as general catch-ups. Prepare tight materials, because nobody has time for a long presentation during that week. Book accommodation early, as costs are notoriously extreme and availability vanishes. Plan the logistics realistically, since moving between meetings takes longer than you think and overpacking your schedule guarantees you will be late and frazzled. And plan your follow-up before you go, because the deals happen in the weeks afterward, not during the week itself.
Getting real value
The people who benefit most treat the week as a campaign rather than a trip. They know exactly who they want to meet and why, they secure those meetings early, they show up prepared and concise, and they follow up rigorously afterward while the conversation is fresh. They also recognize that much of the value is in the unplanned encounters that density makes possible, so they build a little slack into the schedule. And they measure the outcome afterward, honestly, against what they set out to achieve, which is the only way to decide whether to go again.
The bottom line
JPM 2027 will once again concentrate the industry’s decision-makers, capital, and attention into a single expensive week, and it will reward those who arrive with a plan and punish those who arrive hoping something will happen. Expect obesity, M&A, capital markets, China, manufacturing, and pricing to dominate the conversation. Decide honestly whether you have a concrete reason to be there, and if you do, start booking your meetings far earlier than feels necessary, because the value of that week is determined almost entirely by the calendar you build before you arrive.
The alternatives worth considering
Given the extraordinary cost and intensity of the week, it is worth asking honestly whether JPM is actually the right venue for your objectives, because for many companies it is not and the money is better deployed elsewhere. If your goal is business development, the dedicated partnering conferences, where the entire event is structured around one-to-one meetings with a proper partnering system, are often more productive than the chaos of San Francisco in January, where meetings are scattered across the city and everyone is exhausted. If your goal is scientific engagement and visibility with clinicians and researchers, the major medical and scientific congresses in your therapeutic area deliver far more than a finance-focused conference will. If your goal is investor outreach and you are not at a stage where the density of JPM helps, targeted roadshows and direct outreach are cheaper and can be more effective. And if you are a small company with no news, no meetings booked, and no specific objective, the honest answer is often that you should not go at all, and that the tens of thousands of dollars the week costs would do more good almost anywhere else. This is not an argument against JPM, which remains genuinely valuable for those with the right objectives and the preparation to pursue them. It is an argument for making the decision deliberately, based on a clear-eyed assessment of what you actually need to accomplish and whether that week is the best way to accomplish it, rather than attending because everyone else does and the fear of missing out is powerful. The companies that get the most from the industry’s conference calendar are those that choose their events strategically rather than reflexively.
The bottom line, restated
JPM 2027 will reward preparation and punish improvisation, as it always does. Decide honestly whether you have a concrete reason to be there. If you do, start booking meetings far earlier than feels necessary, set an objective for each one, prepare tight materials, and plan your follow-up before you land, because the deals happen in the weeks afterward. And if you do not have a clear objective, consider whether a partnering conference, a scientific congress, or simply staying home and spending the money on something else would serve you better. The best conference strategy is a selective one.
Book the meetings, then book the flight
The sequence matters. Companies that book travel and hope to fill their calendar arrive with gaps and leave disappointed. Companies that secure their meetings first and then commit to the trip arrive with a purpose and a full schedule. Start outreach in the autumn, be specific about why the meeting is worth someone’s scarce January time, and be willing to skip the week entirely if the calendar does not materialize. A JPM trip with six great meetings is a success; a JPM trip with a great hotel and no meetings is an expensive lesson.
For the full calendar of industry events, browse the BioMed Nexus conferences directory, and see our guides on navigating JPM and getting real ROI from a biotech conference.
Frequently asked questions
What is the JPMorgan Healthcare Conference?
It is the biotech industry's most important annual gathering, held each January in San Francisco, where companies present to investors and deals get announced. The formal presentations are only a fraction of the value; the real event is the enormous surrounding ecosystem of thousands of private meetings, satellite events and receptions across the city.
Is the JPMorgan Healthcare Conference worth attending?
It is worth it if you are raising money and can use the density of investors, doing business development with meaningful partner meetings booked, a public company engaging investors, or a service provider whose customers attend. It is not worth the substantial cost if you have no specific meetings, no news to share, and no concrete objective.
How should I prepare for JPM?
Start booking meetings months ahead, since calendars fill remarkably early and the best slots are gone by December. Set a clear objective for each meeting, prepare tight materials because nobody has time for long presentations, book accommodation early given extreme costs, plan logistics realistically, and plan your follow-up before you go, since deals happen in the weeks afterward.
